MedTrace Logo

Study of Dolutegravir (DTG) on PK of Cenicriviroc (CVC), and CVC on PK of DTG & on a Single Dose of Midazolam

NCT01827540 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2014-04-09

No results posted yet for this study

Summary

To evaluate the PK, safety and tolerability of Cenicriviroc (CVC) administered with and without Dolutegravir (DTG) and CVC with and without a single dose of Midazolam in healthy subjects.

Conditions

  • HIV-infection/AIDS

Interventions

DRUG

Cenicriviroc

DRUG

Dolutegravir

DRUG

Midazolam

Sponsors & Collaborators

  • ViiV Healthcare

    collaborator INDUSTRY

  • Tobira Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Audrey Martinez, MD · SeaView Research, Inc.

Study Design

Allocation
NON_RANDOMIZED
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2013-05-31
Completion
2013-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01827540 on ClinicalTrials.gov